
Elvina Almuradova/LinkedIn
Jan 31, 2025, 07:20
Elvina Almuradova: Pertuzumab + trastuzumab retreatment to prolong OS in HER2+ metastatic breast cancer
Elvina Almuradova, Medical Oncologist Ambassador at European School of Oncology, shared on X:
“PRECIOUS study:
Pertuzumab + trastuzumab retreatment
prolonged OS in HER2+ metastatic breast cancer!
OS: 36.2 months (PTC) vs. 26.5 months (TC)
PFS: investigator-assessed): 5.5 months (PTC) vs. 4.2 months (TC).”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 1, 2025, 17:02
Mar 1, 2025, 16:29
Mar 1, 2025, 15:32
Mar 1, 2025, 15:20
Mar 1, 2025, 15:12
Mar 1, 2025, 14:44
Mar 1, 2025, 14:24